5-Amino-1MQ
Also known as: 5-amino-1-methylquinolinium, NNMT inhibitor
5-Amino-1MQ (also called 5-amino-1-methylquinolinium or NNMT inhibitor) is a small molecule in the NNMT Inhibitor class. 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. That reaction removes nicotinamide from the salvage pathway that regenerates NAD+, and it consumes methyl groups.
For research use only.
Key Facts
- CAS
- 42464-96-0
- Molecular Weight (MW)
- 286.11 g/mol
- Half-life
- 3.8-6.9 hours
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Sep 6, 2026
- Reviewed
- Aug 30, 2026
- Targets
- NNMTNAD+ salvage pathway
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 27
- Listed offers
- 43
- Median price per mg
- $6.81/mg
- Typical $2.91–$8.00/mg
Research summary
Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor studied for NAD+ metabolism and body-composition research. Not an FDA-approved drug.
Peptide Library's 5-Amino-1MQ profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
5-Amino-1MQ dosage: no established human dose
5-Amino-1MQ has no established human dosage. No trial of it is registered on ClinicalTrials.gov and no human study of it is indexed in PubMed. Everything known about it comes from cell and rodent work on nicotinamide N-methyltransferase inhibition. It is also not a peptide - it is a small-molecule quinolinium compound - despite being sold alongside peptides.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: 5-Amino-1MQ is an inhibitor of nicotinamide N-methyltransferase, an enzyme implicated in adipocyte metabolism. The interest in it rests on rodent work in which NNMT inhibition reduced fat mass in diet-induced obese mice, together with in vitro studies of the enzyme. No human has been reported to receive it in an indexed study, so there is no human dose, route, interval or safety profile, and rodent dosing is not converted into a human equivalent here.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-09-05 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — NNMT inhibition in obesity-related metabolic dysfunctionPreclinical · Preclinical rodent study | Diet-induced obese mice | Model-specific; not convertible to a human dose | Intraperitoneal | — | — | Adipose mass and metabolic parameters | Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024. |
Where sources disagree
- Oral protocols of 50-150 mg daily are widely published for 5-Amino-1MQ. No registered trial and no indexed human study reports any dose, and no primary source for those figures could be identified.
- 5-Amino-1MQ is a small-molecule quinolinium salt, not a peptide. It is sold and discussed alongside peptides, but it shares neither their structure nor their handling requirements.
- Rodent results for NNMT inhibition are frequently presented as if they established a human fat-loss effect. They did not, and no human trial has tested the hypothesis.
Handling & administration
- Reconstitution Guide
- N/A (capsule form common)
- Concentration Example
- N/A
- Timing Notes
- With meals to minimize GI upset; morning/midday.
- Expected Onset
- 1-2 weeks for metabolic effects
- Discontinuation
- Taper if needed
Sequence & molecular data
| Amino acid sequence | N/A (small-molecule NNMT inhibitor; not a peptide) |
|---|---|
| Molecular formula | C10H11IN2 |
| Molecular weight | 286.11 g/mol |
| CAS number | 42464-96-0 |
| Half-life | 3.8-6.9 hours |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 950107 |
| ChEMBL | CHEMBL4116828 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. That reaction removes nicotinamide from the salvage pathway that regenerates NAD+, and it consumes methyl groups. NNMT is highly expressed in white adipose tissue and liver and is upregulated in obesity. Inhibiting it is proposed to preserve the nicotinamide pool available for NAD+ synthesis and to alter adipocyte metabolism, and in rodent models NNMT knockdown or inhibition reduced fat mass and improved metabolic parameters on a high-fat diet. It is a small molecule rather than a peptide, and no human trials have been published.
Origin
Synthetic quinolinium small molecule; not a peptide.
Targets
Studies
- Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation
- Nicotinamide N-Methyltransferase (NNMT) and Liver Cancer: From Metabolic Networks to Therapeutic Targets
- Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy
- Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target
- Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation
Regulatory & research status
5-Amino-1MQ is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
5-Amino-1MQ side effects
5-Amino-1MQ has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Limited human safety data
- GI upset reported anecdotally
- Unknown long-term effects
Contraindications
- Liver/kidney issues
- Hypersensitivity
Stacking
Common stacking partners
Combinations that include 5-Amino-1MQ, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
5-Amino-1MQ: frequently asked questions
What is 5-Amino-1MQ?
Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor studied for NAD+ metabolism and body-composition research. Not an FDA-approved drug.
How does 5-Amino-1MQ work?
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. That reaction removes nicotinamide from the salvage pathway that regenerates NAD+, and it consumes methyl groups.
Is 5-Amino-1MQ FDA approved?
No. 5-Amino-1MQ is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of 5-Amino-1MQ?
Reported half-life for 5-Amino-1MQ is 3.8-6.9 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of 5-Amino-1MQ?
5-Amino-1MQ has the sequence N/A (small-molecule NNMT inhibitor; not a peptide), giving a chain of 2 amino acids. Its molecular formula is C10H11IN2.
What peptides are similar to 5-Amino-1MQ?
Compounds most often compared with 5-Amino-1MQ include SLU-PP-332, BAM15, AICAR and Tesofensine. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- PubChem 5-Amino-1MQExternal reference
- Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation — Trends Pharmacol Sci, 2026External reference
- Nicotinamide N-Methyltransferase (NNMT) and Liver Cancer: From Metabolic Networks to Therapeutic Targets — Biomolecules, 2025External reference
- Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy — Front Oncol, 2022External reference
- Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target — Drug Discov Today, 2021External reference
- Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation — Mol Metab, 2021External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 6, 2026 · Version 2
This 5-Amino-1MQ profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track 5-Amino-1MQ research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →